NLG-0505: Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR) (H-32864)
NLG-0505: A Phase III Study of FOLFIRINOX With or Without HyperAcute® - Pancreas (algenpantucel-L) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (H-32864):
The purpose of this study is to see whether adding the investigational immunotherapy to the standard of care regimen FOLFIRINOX increases survival of patients with borderline resectable or unresectable pancreatic cancer. Eligible patients must have a histological diagnosis of pancreatic cancer without distant metastases and disease defined as borderline or locally advanced unresectable as determined by the NCCN guidelines. Patients will be randomized to receive FOLFIRINOX with or without HyperAcute® - Pancreas immunotherapy.
For more information: http://clinicaltrials.gov/show/NCT01836432